The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Veterans affairs seamless phase II/III randomized trial of standard systemic therapy with or without PET-directed local therapy for oligorecurrent prostate cancer (VA STARPORT).
 
Abhishek A Solanki
Honoraria - DAVA Oncology; Novocure; Varian Medical Systems
Consulting or Advisory Role - Novocure
Research Funding - blue earth diagnostics
Travel, Accommodations, Expenses - Novocure; Varian Medical Systems
 
Christopher A Schroth
No Relationships to Disclose
 
Caitlin Authier
No Relationships to Disclose
 
Kimberly Carlson
No Relationships to Disclose
 
Isla Garraway
No Relationships to Disclose
 
Tamara Haegerich
No Relationships to Disclose
 
Elizabeth Henry
Employment - theMednet
Consulting or Advisory Role - Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb (Inst); Nektar (Inst); Seattle Genetics/Astellas (Inst)
Other Relationship - theMednet
 
Jeffrey A Jones
No Relationships to Disclose
 
Remya Joseph
No Relationships to Disclose
 
Thomas Koppes
No Relationships to Disclose
 
Drew Moghanaki
Consulting or Advisory Role - Accuray; AstraZeneca
 
Marcus Lee Quek
No Relationships to Disclose
 
Matthew Rettig
Stock and Other Ownership Interests - ARavalent; Oncovalent Therapeutics; Survalent
Consulting or Advisory Role - Ambrx; Amgen; Clovis Oncology; Roivant
Speakers' Bureau - Bayer; Johnson & Johnson
Research Funding - Johnson & Johnson (Inst); Medivation/Astellas (Inst); Novartis (Inst); Progenics
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent for novel inhibitors of the N-terminal domain of the AR. There are NO commercial partnerships as of yet.
Travel, Accommodations, Expenses - Johnson & Johnson
 
Tammy Rhoda
No Relationships to Disclose
 
Timothy Ritter
No Relationships to Disclose
 
Lisa Robin
No Relationships to Disclose
 
Joseph Kamel Salama
Consulting or Advisory Role - Iovance Biotherapeutics (I); Novartis (I); Pfizer (I); Regeneron (I)
Research Funding - AbbVie; Bristol-Myers Squibb (I); Dynavax Technologies (I); Exact Sciences (Inst); Immunocore (I); Merck (I)
 
Elinore Zacny
No Relationships to Disclose
 
Nicholas George Nickols
No Relationships to Disclose